SkinBioTherapeutics (LSE:SBTX) has appointed interim chief executive Rachel Parsonage to its board of directors after completing the required regulatory due diligence process by the company’s nominated adviser.
Parsonage brings more than 25 years of leadership experience in the consumer beauty and wellness sectors, having guided businesses through periods of expansion and organisational change. Her appointment comes at a pivotal time for the Newcastle-based life sciences company as it focuses on internal engagement with employees and commercial partners while awaiting the outcome of an external investigation and preparing its upcoming half-year financial results.
The group continues to build its business around its proprietary SkinBiotix technology platform, which underpins both cosmetic skincare products and gut–skin axis supplements. Partnerships such as Croda’s Zenakine-branded active ingredient and retail distribution through channels including Amazon and Superdrug form part of its strategy to expand market presence. The company is also pursuing acquisitions aimed at strengthening distribution networks, geographic reach and manufacturing capabilities.
From an investment perspective, the company’s outlook remains constrained by ongoing operating losses and negative operating and free cash flow, despite strong revenue growth. Technical indicators also remain weak, with the share price trading in a clear downtrend across major moving averages and showing bearish momentum signals. Valuation metrics are difficult to assess given the negative price-to-earnings ratio and the absence of dividend yield support.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix platform developed in collaboration with the University of Manchester. The company’s core strategy targets the skin healthcare market through cosmetic skincare and gut–skin axis nutritional supplements, supported by commercial partnerships such as Croda’s Zenakine and retail distribution through platforms including Amazon and Superdrug.
Listed on AIM since 2017 and headquartered in Newcastle, the group is pursuing a consolidator strategy within the skincare and cosmetics sector, acquiring complementary businesses to broaden distribution, enhance manufacturing capacity and accelerate the growth of its in-house brands, including SkinBiotix and AxisBiotix.
Leave a Reply